Does immunosuppressive therapy influence the recovery of bone disease in kidney transplant recipients?
Gonzalez
M T
MT
Department of Nephrology, Hospital de Bellvitge, Barcelona, Spain.
Gonzalez
C
C
Bover
J
J
Bonnin
R
R
Mariñoso
M L
ML
Serrano
S
S
Castelao
A M
AM
Griño
J M
JM
Alsina
J
J
D000328:Adult; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002114:Calcinosis / Q000209:etiology; D002117:Calcitriol / Q000627:therapeutic use; D002118:Calcium / Q000097:blood; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006801:Humans; D006961:Hyperparathyroidism / Q000209:etiology / Q000628:therapy*; D007165:Immunosuppression Therapy; D007676:Kidney Failure, Chronic / Q000503:physiopathology* / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D013256:Steroids / Q000627:therapeutic use
D013256:Steroids; D000536:Aluminum Hydroxide; D016572:Cyclosporine; D002117:Calcitriol; D001379:Azathioprine; D002118:Calcium